Laboratory for Neurodegenerative Disease Research, Clinical Research Center, Chiba East National Hospital, Japan.
Neurobiol Dis. 2012 Jan;45(1):329-36. doi: 10.1016/j.nbd.2011.08.017. Epub 2011 Aug 25.
Anticholinergics, and drugs with anticholinergic properties, are widely and frequently prescribed, especially to the elderly. It is well known that these drugs decrease cognitive function and increase the risk of dementia. Although the mechanism of anticholinergic drug-induced cognitive impairment has been assumed to be functionally reduced acetylcholine (ACh) neurotransmission, some data have indicated that anticholinergics might enhance the pathology of Alzheimer's disease. In this study, we investigated the pathological effects of anticholinergics on neurodegeneration. We chronically administered two anticholinergics, trihexyphenidyl (TP) and propiverine (PP) (the latter with less central anticholinergic action), to neurodegenerative tauopathy model mice 2 to 10 months old. Furthermore, because the ACh nervous system regulates both central and peripheral inflammation, we administered TP or PP to PS19 mice in which we had artificially induced inflammation by lipopolysaccharide injection. Tau pathology, synaptic loss, and neurodegeneration in the hippocampal region, as well as tau insolubility and phosphorylation, were markedly increased in TP-treated mice and mildly increased in PP-treated mice. Furthermore, immunohistochemical analysis revealed microglial proliferation and activation. Moreover, anticholinergics increased interleukin-1β expression in both the spleen and brain of the tauopathy model mice intraperitoneally injected with lipopolysaccharide to induce systemic inflammation. Interestingly, these alterations were more strongly observed in TP-treated mice than in PP-treated mice, consistent with the level of central anticholinergic action. Anticholinergic drugs not only impair cognitive function by decreased ACh neurotransmission, but also accelerate neurodegeneration by suppressing an ACh-dependent anti-inflammatory system. Anticholinergics should be less readily prescribed to reduce the risk of dementia.
抗胆碱能药物和具有抗胆碱能特性的药物被广泛和频繁地开处,尤其是在老年人中。众所周知,这些药物会降低认知功能,增加痴呆的风险。虽然抗胆碱能药物引起认知障碍的机制被认为是功能性乙酰胆碱 (ACh) 神经传递减少,但一些数据表明抗胆碱能药物可能会增强阿尔茨海默病的病理学。在这项研究中,我们研究了抗胆碱能药物对神经退行性变的病理影响。我们给神经退行性 tau 病模型小鼠慢性施用两种抗胆碱能药物,三己芬迪(TP)和丙哌维林(PP)(后者具有较少的中枢抗胆碱能作用),年龄为 2 至 10 个月。此外,由于 ACh 神经系统调节中枢和外周炎症,我们给 PS19 小鼠施用 TP 或 PP,我们通过注射脂多糖人为诱导炎症。TP 治疗的小鼠的 tau 病理学、突触丢失和海马区神经退行性变以及 tau 不溶性和磷酸化明显增加,PP 治疗的小鼠则轻度增加。此外,免疫组织化学分析显示小胶质细胞增殖和激活。此外,抗胆碱能药物增加了脂多糖腹腔内注射诱导全身性炎症的 tau 病模型小鼠脾脏和大脑中的白细胞介素-1β表达。有趣的是,与 PP 治疗的小鼠相比,这些改变在 TP 治疗的小鼠中更为明显,与中枢抗胆碱能作用的水平一致。抗胆碱能药物不仅通过减少 ACh 神经传递来损害认知功能,还通过抑制 ACh 依赖性抗炎系统来加速神经退行性变。为了降低痴呆的风险,应减少开处抗胆碱能药物。